| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | ||
| 3 | Generic | etrasimod | |
| 4 | Economics | Acquired Arena | |
| 5 | MOA | S1P | |
| 6 | Indications | Ulcerative Colitis | |
| 7 | Regulatory | Filing 2022 | |
| 8 | Clinical Trials | ||
| 9 | Phase III "ELEVATE UC 12" | ||
| 10 | 24.8% remission vs. 15.2% p=0.0264 | ||
| 11 | |||
| 12 | Phase III "ELEVATE UC 52" | ||
| 13 | 27% remission vs. 7.4% at week 12 | ||
| 14 | 32% remission vs. 6.7% at week 52 |